Strain Data Sheet
Data update: Jul 19, 2019
Health Report   PCR Protocol   Thawing Method
embryos / sperm >
  Mouse Marking
RBRC No. RBRC00306  
Type Targeted MutationCartagena   4wks
Species Mus musculus  
Strain name TNF.K.O  
Former Common name No Data  
H-2 Haplotype No Data  
ES cell line W9.5 [129S1/Sv-Oca2<+> Tyr<+> Kitl<+>]  
Donor strain 129S1/Sv-p+ Tyr+ Kitl+ via W9.5 ES cell line  
Background strain C57BL/6JJcl  
 1 Appearance black  
Genotype a/a B/B C/C  
Strain development Developed by Drs. Michael W Marion and Lloyd J. Old, Ludwig Institute for Cancer Research in 1999. Neomycin cassettes were inserted into the nucleotides 3704-5364 of the Tnf gene.  
Strain description B6.129S1-Tnf<tm1Ljo>/Rbrc. TNF, tumor necrosis factor is a multifunction proinflammatory cytokine, play a critical role in regulating of the development and function of the immune system. Homozygous mutant mice show no cytotoxicity of TNF.  
Colony maintenance Homozygote x Homozygote
Homozygous mutant mice show a normal development and no gross morphological abnormalities.  
Health Report No Data  
Gene Details
Promoter No Data  
 1 Symbol Tnf  
Symbol name tumor necrosis factor  
Chromosome 17  
Common name tumor necrosis factor alpha, DIF, Tnfa, TNFSF2, TNFalpha, TNF-alpha, TNF alpha, Tnfsf1a, tumor necrosis factor-alpha  
Symbol description No Data  
Promoter mouse phosphoglycerate kinase promoter (PGK promoter)  
 2 Symbol neo  
Symbol name neomycin resistance gene (E. coli)  
Chromosome 17  
Common name neo; neomycin;  
Symbol description No Data  
References Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8093-8.  
Characterization of tumor necrosis factor-deficient mice.
Research applications No Data  
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Inquiries regarding the use of the BIOLOGICAL RESOURCE for commercial purposes including research use by for-profit companies should be directed to:
Dr. Par Olsson
Director, Intellectual Property
Ludwig Institute for Cancer Research
666 Third Avenue
New York, NY 10017
Tel. +1-212-450-1500
Fax. +1-212-450-1535
Ownership of modifications and derivatives including crossed progeny of the BIOLOGICAL RESOURCE will be determined in accordance with applicable law governing inventorship and the creative input of the parties and the Recipient agrees to report any such progeny to LICR. The RIKEN BRC, the LICR and Recipient agree that no party will license or otherwise commercialize any such invention in the absence of an agreement to be negotiated in good faith by the parties hereto, providing for, inter alia, the sharing of royalty income.  
Additional information
 1 No Data  
 2 Genotyping protocol <PCR>  
Depositor Gerd, Ritter (Ludwig Institute for Cancer Research)  Gerd, Ritter 
Strain Status /
(Expected delivery)

back Back
RIKEN BioResource Research Center

English page click here ANIMAL SEARCH SYSTEM